论文部分内容阅读
目的:探讨华蟾素注射液联合胸腔热灌注治疗恶性胸腔积液的临床疗效与不良反应。方法:临床随机选择25例经胸水脱落细胞学检查证实为恶性胸腔积液的患者进行华蟾素注射液联合胸腔热灌注治疗,观察其胸水控制率、肿瘤指标下降程度、免疫状态改变与不良反应。结果:25例患者治疗结束后4周进行疗效评估,胸水控制总有效率为88%,治疗后患者免疫状态较治疗前有所改善,肿瘤标志物水平较治疗前有所降低,且治疗过程中无严重不良反应,无明显血液学毒性反应,未发生治疗相关性死亡。结论:华蟾素注射液结合胸腔热灌注治疗恶性胸腔积液患者,疗效确切,并发症少,安全性高,患者耐受性好,值得临床推广。
Objective: To investigate the clinical efficacy and adverse reactions of cinobufagin injection combined with pleural hyperthermic perfusion in the treatment of malignant pleural effusion. Methods: 25 cases of malignant hydrothorax confirmed by hydrothorax cytology were randomized to receive cinobufacini injection combined with intraperitoneal hyperthermic perfusion. The control rate of pleural effusion, the degree of tumor reduction, the change of immune status and adverse reactions . Results: After 25 weeks of treatment, the curative effect was evaluated in 4 weeks. The total effective rate of pleural effusion control was 88%. After treatment, the immune status of patients was improved compared with that before treatment. The level of tumor markers was lower than that before treatment. No serious adverse reactions, no significant hematological toxicity, no treatment-related deaths. Conclusion: Cinobufagin injection combined with pleural heat perfusion in the treatment of patients with malignant pleural effusion, curative effect is accurate, less complications, high safety, patient tolerance is good, worthy of clinical promotion.